Trial site
Urology Associates, P.C.
Nashville, Tennessee 37209, United StatesNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 13 trials
- Phase 1/22 trials
- Phase 22 trials
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Completed2 trials
- Terminated1 trial
- Lead sponsor
- Pfizer3 trials
- Sumitomo Pharma America, Inc.2 trials
- Aura Biosciences1 trial
- CG Oncology, Inc.1 trial
- Clarity Pharmaceuticals Ltd1 trial
- and 9 more
Running trials
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947· Phase 2· Tyra Biosciences, Inc· Source
Contact: Lara Balick
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225· Phase 1· Pfizer· Source
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963· Phase 1/2· ImmunityBio, Inc.· Source
Contact: Nathaniel Kelly
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Active, not recruiting
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847· Phase 3· Clarity Pharmaceuticals Ltd· Source
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· Phase 3· Ferring Pharmaceuticals· Source
Contact: Ferring Pharmaceuticals
Active, not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· Phase 3· CG Oncology, Inc.· Source
Active, not recruiting
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868· Phase 1· Aura Biosciences· Source
Active, not recruiting
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550· Phase 3· UroGen Pharma Ltd.· Source
Recruiting
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423· Phase 2· Zenith Epigenetics· Source
Contact: Zenith Study Team
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Contact: Jayram
Recruiting
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
NCT07673016· Convergent Genomics, Inc.· Source
Active, not recruiting
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
NCT03933826· University of Washington· Source
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error